Literature DB >> 26609329

Myeloproliferative Neoplasms in Children.

Inga Hofmann1.   

Abstract

Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell disorders characterized by aberrant proliferation of one or more myeloid lineages often with increased immature cells in the peripheral blood. The three classical BCR-ABL-negative MPNs are: 1) polycythemia vera (PV), 2) essential thrombocythemia (ET), and 3) primary myelofibrosis (PMF), which are typically disorders of older adults and are exceedingly rare in children. The diagnostic criteria for MPNs remain largely defined by clinical, laboratory and histopathology assessments in adults, but they have been applied to the pediatric population. The discovery of the JAK2 V617F mutation, and more recently, MPL and CALR mutations, are major landmarks in the understanding of MPNs. Nevertheless, they rarely occur in children, posing a significant diagnostic challenge given the lack of an objective, clonal marker. Therefore, in pediatric patients, the diagnosis must rely heavily on clinical and laboratory factors, and exclusion of secondary disorders to make an accurate diagnosis of MPN. This review focuses on the clinical presentation, diagnostic work up, differential diagnosis, treatment and prognosis of the classical BCR-ABL-negative MPNs (PV, ET and PMF) in children and highlights key differences to the adult diseases. Particular attention will be given to pediatric PMF, as it is the only disorder of this group that is observed in infants and young children, and in many ways appears to be a unique entity compared to adult PMF.

Entities:  

Keywords:  Myeloproloferative neoplasms; essential thrombocythemia; pediatric myeloproliferative neoplasms; polycythemia vera; primary myelofibrosis

Year:  2015        PMID: 26609329      PMCID: PMC4655194          DOI: 10.1007/s12308-015-0256-1

Source DB:  PubMed          Journal:  J Hematop        ISSN: 1865-5785            Impact factor:   0.196


  89 in total

Review 1.  Conventional cytogenetics in myelofibrosis: literature review and discussion.

Authors:  Kebede Hussein; Daniel L Van Dyke; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2009-01-09       Impact factor: 2.997

2.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

Authors:  N Gangat; A P Wolanskyj; R F McClure; C-Y Li; S Schwager; W Wu; A Tefferi
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

Review 3.  Idiopathic erythrocytosis, diagnosis and clinical management.

Authors:  T C Pearson; M Messinezy
Journal:  Pathol Biol (Paris)       Date:  2001-03

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 5.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

Authors:  Francesco Passamonti; Elisa Rumi; Luca Arcaini; Emanuela Boveri; Chiara Elena; Daniela Pietra; Sabrina Boggi; Cesare Astori; Paolo Bernasconi; Marzia Varettoni; Ercole Brusamolino; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2008-09-11       Impact factor: 9.941

Review 7.  Polycythemia vera: diagnosis and treatment 2002.

Authors:  Nathaniel I Berlin
Journal:  Expert Rev Anticancer Ther       Date:  2002-06       Impact factor: 4.512

8.  Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Authors:  Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Robin Foà; Luigi M Larocca
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

9.  Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

Authors:  Alexandra P Wolanskyj; Susan M Schwager; Rebecca F McClure; Dirk R Larson; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2006-02       Impact factor: 7.616

10.  The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy.

Authors:  Polina Stepensky; Ann Saada; Marianne Cowan; Adi Tabib; Ute Fischer; Yackov Berkun; Hani Saleh; Natalia Simanovsky; Aviram Kogot-Levin; Michael Weintraub; Hamam Ganaiem; Avraham Shaag; Shamir Zenvirt; Arndt Borkhardt; Orly Elpeleg; Nia J Bryant; Dror Mevorach
Journal:  Blood       Date:  2013-04-18       Impact factor: 22.113

View more
  11 in total

1.  Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.

Authors:  Mehmet Enes Coskun; Sue Height; Anil Dhawan; Nedim Hadzic
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  G6b-B: the "Y's" and wherefores.

Authors:  Debra K Newman
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

3.  A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era.

Authors:  Xiu-Peng Ye; Shen Bao; Huan-Min Gao; Ying Guo; Yu-Ping Wei
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

Review 4.  Myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Henrik Hasle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.

Authors:  K Hussein; A Stucki-Koch; G Göhring; H Kreipe; M Suttorp
Journal:  Leukemia       Date:  2017-02-27       Impact factor: 11.528

6.  Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.

Authors:  Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2021-07-30       Impact factor: 3.673

Review 7.  Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.

Authors:  Nicole Kucine
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

8.  Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice.

Authors:  Inga Hofmann; Mitchell J Geer; Timo Vögtle; Andrew Crispin; Dean R Campagna; Alastair Barr; Monica L Calicchio; Silke Heising; Johanna P van Geffen; Marijke J E Kuijpers; Johan W M Heemskerk; Johannes A Eble; Klaus Schmitz-Abe; Esther A Obeng; Michael Douglas; Kathleen Freson; Corinne Pondarré; Rémi Favier; Gavin E Jarvis; Kyriacos Markianos; Ernest Turro; Willem H Ouwehand; Alexandra Mazharian; Mark D Fleming; Yotis A Senis
Journal:  Blood       Date:  2018-06-13       Impact factor: 22.113

Review 9.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

10.  Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?

Authors:  Tariq I Mughal; Michael W Deininger; Nicole Kucine; Giuseppe Saglio; Richard A Van Etten
Journal:  Hemasphere       Date:  2019-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.